T-cell receptor recognizing hemagglutinin-derived peptide–MHC complexes (HA-specific TCR)

The T-cell receptor (TCR) recognizing hemagglutinin-derived peptide–MHC complexes is a specialized immune receptor responsible for identifying influenza virus-infected cells (NCBI, 2023). It consists of alpha and beta polypeptide chains that form a binding pocket specific to peptides derived from the influenza hemagglutinin (HA) protein, typically presented by MHC Class I or Class II molecules (UniProt, 2024). Upon binding, the TCR complex undergoes conformational changes that trigger downstream signaling through the CD3 complex, leading to T-cell activation and proliferation (PubMed, 2022). This specific TCR is a critical component of the adaptive immune response to influenza and serves as a primary model in immunological research for studying T-cell development and tolerance (Nature, 2021). In a clinical context, HA-specific TCRs are explored for the development of TCR-engineered T-cell therapies and as targets for universal influenza vaccines (ClinicalTrials.gov, 2023). The interaction between the TCR and the HA-peptide-MHC complex is highly sensitive to viral mutations, which can lead to immune evasion through antigenic drift (Science, 2020). Therapeutic strategies often aim to identify conserved HA epitopes to ensure broad-spectrum protection across different influenza strains (Cell, 2022). Safety concerns associated with utilizing these TCRs include potential cross-reactivity with human self-peptides and the risk of cytokine release syndrome during adoptive cell transfer (Nature Reviews Immunology, 2021).

Other names

Influenza hemagglutinin-specific T-cell receptorHA-TCRHemagglutinin-specific TCRTCR recognizing HA peptide-MHC

The TCR binds specifically to the hemagglutinin peptide presented by MHC molecules, initiating intracellular signaling through the CD3 complex to activate the T cell's effector functions against infected cells (PubMed, 2022).